Ascendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024. In the quarter to June 2026, revenue grew 119.9%, EPS grew 612.3%, free cash flow grew 2,335.9% and total debt fell 41.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow ASND
Ascendis Pharma A/S (ASND) EV/Sales
As of 16 October 2026, Ascendis Pharma A/S (ASND) trades at a EV/Sales of 11.6×. Over the past ten years it has ranged from 0.0× (September 2015) to 6,182× (October 2018); the current reading is higher than 6% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.2× | (23.04%) |
| FY2024 | 21.1× | (17.09%) |
| FY2023 | 25.4× | (79.02%) |
| FY2022 | 121× | (83.32%) |
| FY2021 | 726× | (25.44%) |
| FY2020 | 974× | 149.69% |
| FY2019 | 390× | 116.97% |
| FY2018 | 180× | (72.19%) |
| FY2017 | 646× | 900.06% |
| FY2016 | 64.6× | 92.52% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.8× | (4.95%) |
| Mar 2026 | 14.5× | (10.40%) |
| Dec 2025 | 16.2× | (5.51%) |
| Sep 2025 | 17.2× | (14.55%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| EXEL Exelixis, Inc. compare | 6.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| ASND Ascendis Pharma A/S | 11.6× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)